Aileron Therapeutics (ALRN) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ALRN Aileron Therapeutics

Watchlist

1.7500
-0.0100-0.57%

Close Dec 20 16:00 ET

37.92MMarket Cap-0.61P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Aileron Therapeutics Shares Are Trading Lower. The Company Reported Q3 Financial Results
BenzingaNov 15 11:20 ET
Aileron Therapeutics GAAP EPS of -$0.27 Misses by $0.02
Seeking AlphaNov 15 06:39 ET
Aileron Therapeutics | 10-Q: Q3 2024 Earnings Report
SECNov 14 17:19 ET · Announcements
Express News | Aileron Therapeutics, Inc. Q3 Net Income USD -5.847 Million
ReutersNov 14 16:15 ET
Press Release: Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Dow JonesNov 14 16:15 ET
Aileron Therapeutics 3Q Loss/Shr 27c >ALRN
Dow JonesNov 14 16:15 ET

Comments

Trytosaveabit

Oct 31 06:44

Update

$Aileron Therapeutics (ALRN.US)$ Advancium Paid Aileron Non-Refundable Fee for Exclusive Option to Acquire ALRN-6924 and Related Assets >ALRN
Dow Jones· 4 mins ago

Jaguar8

Oct 31 06:34

NEWS

$Aileron Therapeutics (ALRN.US)$
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
Aileron Therapeutics (NASDAQ: ALRN) and Advancium Health Network have entered into an exclusive option agreement for ALRN-6924, targeting retinoblastoma, a rare pediatric eye cancer. Advancium paid a non-refundable fee for the option to acquire ALRN-6924, with potential additional payments upon exercise. The drug selecti...

Jaguar8

Oct 14 06:51

NEWS

$Aileron Therapeutics (ALRN.US)$
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
Aileron Therapeutics (NASDAQ: ALRN) is presenting data from its Phase 1b clinical trial of LTI-03 for Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis. The trial's Cohort 1, evaluating low-d...

Stock_Drift

Oct 12 08:08

$Aileron Therapeutics (ALRN.US)$

Trytosaveabit

Sep 23 06:44

Watching for data release

$Aileron Therapeutics (ALRN.US)$ Aileron Therapeutics Completes Enrollment for Phase 1b IPF Drug Trial, Topline Data Expected Soon
Benzinga· 6 mins ago

Heat List

Overall

No Data